DNA Link Inc (KQ:127120) — Market Cap & Net Worth
Market Cap & Net Worth: DNA Link Inc (127120)
DNA Link Inc (KQ:127120) has a market capitalization of $676.82 Million (₩998.73 Billion) as of August 1, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #10548 globally and #267 in its home market, demonstrating a -17.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DNA Link Inc's stock price ₩28950.00 by its total outstanding shares 34498327 (34.50 Million). See DNA Link Inc capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
DNA Link Inc Market Cap History: 2015 to 2026
DNA Link Inc's market capitalization history from 2015 to 2026. Data shows growth from $289.15 Million to $676.82 Million (8.08% CAGR).
Index Memberships
DNA Link Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$202.56 Billion | 0.33% | #53 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$202.56 Billion | 0.33% | #53 of 1384 |
Weight: DNA Link Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
DNA Link Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DNA Link Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
DNA Link Inc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $154.29 Million | $11.48 Billion | -$9.81 Billion | 0.01x | N/A |
| 2017 | $131.02 Million | $14.48 Billion | $337.62 Million | 0.01x | 0.39x |
| 2018 | $91.72 Million | $14.88 Billion | -$3.75 Billion | 0.01x | N/A |
| 2019 | $83.36 Million | $15.57 Billion | -$13.12 Billion | 0.01x | N/A |
| 2020 | $224.20 Million | $15.29 Billion | -$13.07 Billion | 0.01x | N/A |
| 2021 | $110.47 Million | $22.99 Billion | -$5.10 Billion | 0.00x | N/A |
| 2022 | $88.02 Million | $16.98 Billion | -$7.78 Billion | 0.01x | N/A |
| 2023 | $68.15 Million | $21.95 Billion | -$5.60 Billion | 0.00x | N/A |
| 2024 | $132.79 Million | $15.91 Billion | -$10.80 Billion | 0.01x | N/A |
| 2025 | $417.32 Million | $19.32 Billion | -$16.45 Billion | 0.02x | N/A |
Competitor Companies of 127120 by Market Capitalization
Companies near DNA Link Inc in the global market cap rankings as of August 1, 2026.
Key companies related to DNA Link Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
DNA Link Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, DNA Link Inc's market cap moved from $289.15 Million to $ 676.82 Million, with a yearly change of 8.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩676.82 Million | +62.18% |
| 2025 | ₩417.32 Million | +214.26% |
| 2024 | ₩132.79 Million | +94.85% |
| 2023 | ₩68.15 Million | -22.58% |
| 2022 | ₩88.02 Million | -20.32% |
| 2021 | ₩110.47 Million | -50.73% |
| 2020 | ₩224.20 Million | +168.97% |
| 2019 | ₩83.36 Million | -9.11% |
| 2018 | ₩91.72 Million | -30.00% |
| 2017 | ₩131.02 Million | -15.08% |
| 2016 | ₩154.29 Million | -46.64% |
| 2015 | ₩289.15 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of DNA Link Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $676.82 Million USD |
| MoneyControl | $676.82 Million USD |
| MarketWatch | $676.82 Million USD |
| marketcap.company | $676.82 Million USD |
| Reuters | $676.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more